1. China Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
ETHK Labs Inc.

ETHK Labs Inc.

HHKEX:1931
0.36
HKD
+0.03
(+7.46%)
4.20BMarket Cap
Mar 12Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.22
0.25
0.31
2.06
1.83
2.06
2.04
2.28
2.12
1.74
- -
Basic EPS, GAAP
0.04
0.08
0.08
0.24
0.12
0.13
0.16
0.18
0.17
0.02
- -
Free Cash Flow per Basic Share
-0.03
- -
-0.01
0.27
0.11
0.1
0.16
0.19
0.1
-0.62
- -
Dividend per Share
0.02
0.01
- -
0.2
0.06
0.04
0.04
0.06
0.09
0.05
- -
Book Value per Share
0.56
0.63
0.71
2.11
2.16
2.2
2.33
2.47
2.29
1.84
1.84
Tangible Book Value per Share
0.53
0.6
0.69
0.89
0.91
0.98
1.12
1.26
1.28
0.82
0.82
Basic Weighted Avg Shares
1,333
1,333
1,333
1,134
1,330
1,323
1,345
1,352
1,495
1,620
1,615
Sales/Revenue/Turnover
290
338
414
2,333
2,428
2,731
2,749
3,088
3,162
2,821
- -
Operating Margin (%)
10.87
15.11
9.24
8.34
10.27
10.21
13.14
12.67
14.6
7.29
- -
Depreciation Expense
11
15
18
49
38
39
35
38
38
55
- -
Net Income, GAAP
56
111
103
275
159
175
210
238
260
35
- -
Effective Tax Rate (%)
13.46
12.25
15.4
14.19
33.34
39.63
31.1
30.12
33.79
57.6
- -
Profit Margin (%)
19.37
32.74
25.01
11.79
6.54
6.39
7.64
7.71
8.23
1.24
- -
Working Capital
214
253
297
1,281
1,413
1,376
1,529
1,783
2,170
914
914
LT Debt
- -
- -
- -
- -
147
- -
- -
- -
- -
- -
- -
Total Equity
754
853
956
2,806
2,859
2,993
3,153
3,386
3,761
3,011
3,011
Return on Invested Capital (%)
- -
5.85
3.31
6.67
5.16
4.97
7.07
7.51
7.32
1.79
- -
Return on Capital (%)
- -
13.55
11.88
14.9
5.6
5.96
7.09
7.02
6.76
1.23
- -
Return on Common Equity (%)
- -
13.96
11.56
14.6
5.6
5.99
6.85
7.33
7.38
1.05
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
756
1,684
1,927
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,623
1,619
1,602
Market Capitalization
2,745
3,250
3,772

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
3,717
4,342
3,567
Cash, Cash Equivalents & STI
1,858
425
551
Accounts Receivable, Net
484
510
453
Inventories
1,237
3,109
2,288
Total Current Liabilities
1,547
2,420
2,654
Payables & Accruals
- -
- -
- -
ST Debt
756
1,684
1,927
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
1.71%
-19.94%
Free Cash Flow
- -
-150.69%
-780.72%
Net Income, GAAP
- -
-6.71%
-86.59%
Sales/Revenue/Turnover
- -
3.41%
-10.81%
Total Cash Common Dividend
- -
10.25%
-41.3%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
3,088
2024
- -
- -
3,162
2025
- -
- -
2,821

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.18
2024
- -
- -
0.17
2025
- -
- -
0.02

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.06
2024
- -
- -
0.09
2025
- -
- -
0.05

Company Description

Company Profile APIChatGPT
CEO
Xianya Lin
Full Time Employees
910
Sector
Distribution services
Industry
Medical distributors
Address
Building 6 Pudong SH China
IPO Date
Jul 12, 2019
Website
ivdholding.com
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
IVD Medical Holding Limited (1931.HK), an investment holding company incorporated in 2016 and headquartered at Room 602, Block 6, No.1 Shanghai Center, Lane 299, Bisheng Road, Zhangjiang Hi-Tech Park, Shanghai, China, principally engages in the distribution, research, development, manufacturing, and sale of in vitro diagnostic (IVD) products and related medical equipment and consumables, primarily in Mainland China with international reach. The company operates through three key segments: Distribution Business, trading IVD analyzers, reagents, and other consumables to distributors, hospitals, healthcare institutions, and logistics providers; After-sales Services, providing maintenance, repair, installation, and end-customer training; and Self-branded Products Business, focusing on the research, development, manufacturing, and sales of proprietary IVD analyzers and reagents. It serves healthcare customers including hospitals and clinics with products encompassing clinical chemistry, immunoassay, hematology, microbiology, and molecular diagnostics categories. Recent developments include the establishment of a joint venture with ETHK Group in September 2025 to advance on-chain financial strategies; a HK$149 million investment in Ethereum through HashKey Exchange in August 2025 to position as a leading Ethereum Treasury player; ongoing share repurchases, such as 15.29 million shares; and strengthened solution services with enhanced stocking of multi-brand IVD products.